PEOPLE - VidaMed (US) president and Chief Executive Officer to resign:
This article was originally published in Clinica
Executive Summary
James Heisch is to resign as president and CEO of VidaMed, a US manufacturer of advanced systems for the treatment of urological conditions. Mr Heisch said it was now time for VidaMed to recruit a seasoned medical-device executive who would lead the company in the launch of its transurethral ablation system (TUNA) for the treatment of benign prostatic hyperplasia. The system is already FDA-approved.
You may also be interested in...
US CDC’s Adult RSV Vaccine Recommendations In Flux With Impending FDA Approvals
Moderna touts enriched Phase II/III population and severe RSV data as CDC advisory committee re-evaluates shared clinical decision-making and prepares for expected June votes on Moderna’s mRNA-1345 and expanded adult use of GSK’s Arexvy.
Roche Nabs FDA Approval For First Of Its Kind Malaria Test
The US FDA has approved Roche’s cobas Malaria test, which screens blood donors in the US for malaria. The cobas is the first such diagnostic to win agency approval.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.